Drug Type AAV based gene therapy |
Synonyms GC-101, RDGT-002 |
Target |
Mechanism SMN1 gene stimulants(survival of motor neuron 1, telomeric gene stimulants) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationBreakthrough Therapy (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Juvenile Spinal Muscular Atrophy | Phase 2 | CN | 10 May 2024 | |
Muscular Atrophy, Spinal, Type II | Phase 2 | CN | 31 Jul 2023 | |
HMN (Hereditary Motor Neuropathy) Proximal Type I | Phase 2 | CN | 14 Mar 2023 |